Population pharmacokinetics III: design, analysis, and application of population pharmacokinetic Studies.
about
Understanding and applying pharmacometric modelling and simulation in clinical practice and researchEstimation of pharmacokinetic parameters based on the patient-adjusted population data.Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunologyPKreport: report generation for checking population pharmacokinetic model assumptions.Bayesian inference for generalized linear mixed model based on the multivariate t distribution in population pharmacokinetic studyInterpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.Computational opioid prescribing: a novel application of clinical pharmacokinetics.Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients.Population pharmacokinetics of tafenoquine during malaria prophylaxis in healthy subjectsOverview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey.Population pharmacokinetics of high-dose methotrexate after intravenous administration in Chinese osteosarcoma patients from a single institutionA population approach to characterise amisulpride pharmacokinetics in older people and Alzheimer's diseaseNonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women.The role of population PK-PD modelling in paediatric clinical research.Limited-sampling strategies for anti-infective agents: systematic review.Therapeutic D2/3 receptor occupancies and response with low amisulpride blood concentrations in very late-onset schizophrenia-like psychosis (VLOSLP).Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease.Children in clinical trials: towards evidence-based pediatric pharmacotherapy using pharmacokinetic-pharmacodynamic modeling.Quantifying the Exposure of Tapentadol Extended Release in Japanese Patients with Cancer Pain and Bridging Tapentadol Pharmacokinetics Across Populations Using a Modeling Approach.A Longitudinal HbA1c Model Elucidates Genes Linked to Disease Progression on Metformin.Establishing Good Practices for Exposure-Response Analysis of Clinical Endpoints in Drug Development.Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir.Retrospective population pharmacokinetic/pharmacodynamic analysis of pyridostigmine, a cholinesterase inhibitor, in Chinese males.Tailoring care to haemophilia patients' needs: which specialty and when?Chain length of dietary alkylresorcinols affects their in vivo elimination kinetics in rats.Population pharmacokinetics and pharmacogenetics of alcohol in Chinese and Indians in Singapore.Mathematical modeling and simulation in animal health. Part III: Using nonlinear mixed-effects to characterize and quantify variability in drug pharmacokinetics.Population pharmacokinetics of lamotrigine in elderly patients.Bayesian hierarchical model for analyzing multiresponse longitudinal pharmacokinetic data.Measuring the glomerular filtration rate in obese individuals without overt kidney disease.
P2860
Q28468334-9EDE4CEA-2B02-49F6-956B-0E277E35B2B1Q31082856-0FFAB253-1776-4A12-8608-6BA98BFA8355Q33827819-2AC5D160-BF89-4880-A7FD-2726EA305E4DQ33901595-F16814C6-65A5-4A84-9AA1-1DBF181E051AQ34631787-92454411-9DC7-4784-A53A-193E8EFC49CDQ34996894-9307F838-DFA9-44E6-A6D9-DE5A60DEEC81Q35084232-19F8B50C-B597-4B58-8EAA-DE3749953A93Q35363649-3C2B0E03-2B1B-4860-B1A1-D172C00E29F1Q35912649-5BA0C29F-AA7E-47BF-B47F-A8E6447339F1Q36388088-B26AB0B1-8C4E-4549-A3C6-F550E8FC2B1EQ36816150-FA49CCEF-0D32-46B4-9F03-74FF5FD3F104Q37184470-98E09E16-7A80-4693-8300-4322253B8AA0Q37237006-7D140A83-2937-4C77-8749-B10CF5C49437Q37719346-AF9AABA8-A198-4570-AB9A-C3220AFB3A07Q38000241-0DC76F4E-EB71-459B-9552-ECE0D6B2E1F3Q38667647-8E35C9A3-13AE-40EA-8503-79BF4A91000EQ38740848-C057C2BD-7ABC-4ABA-A6EF-FFF28CFCCC7BQ38857191-987F9732-C89A-4D98-BBB3-6E80FA9AF60DQ39181543-4ABECD10-EB09-4AFC-831B-57469E00BA9BQ39602527-10F401B6-CD48-4BEA-A70B-056543A57D79Q41819996-29E8B053-6690-4D60-A29F-F0377ED80BD6Q42286838-2D9E5D2A-F817-4733-9059-B6D3B2BC50EFQ42631585-100ECC15-B469-4428-8DD1-BCABE2159042Q43198121-D58F6C79-E5AE-495A-AE2D-72DBDEB69276Q43451894-BD5A4989-C2D5-46A8-A99F-5C2FF1F35050Q45971534-6D63D82E-E31C-4903-A3FA-59F22429E4EBQ46244052-93195E16-8779-4ADE-9127-33E23C7828F5Q46736452-AB983847-02A5-437A-AAE5-B7F9BC8EE5C8Q47667515-7E554726-79EF-4E2A-981B-4E711ED4E16CQ55053045-DCF885FB-8D70-4A03-9C05-CB5FA971424A
P2860
Population pharmacokinetics III: design, analysis, and application of population pharmacokinetic Studies.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Population pharmacokinetics II ...... ation pharmacokinetic Studies.
@ast
Population pharmacokinetics II ...... ation pharmacokinetic Studies.
@en
type
label
Population pharmacokinetics II ...... ation pharmacokinetic Studies.
@ast
Population pharmacokinetics II ...... ation pharmacokinetic Studies.
@en
prefLabel
Population pharmacokinetics II ...... ation pharmacokinetic Studies.
@ast
Population pharmacokinetics II ...... ation pharmacokinetic Studies.
@en
P2093
P2860
P356
P1476
Population pharmacokinetics II ...... ation pharmacokinetic Studies.
@en
P2093
Ene I Ette
James R Lane
Paul J Williams
P2860
P304
P356
10.1345/APH.1E260
P407
P577
2004-10-26T00:00:00Z